PCG
ALNY icon

Prosperity Consulting Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Prosperity Consulting Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$344K Hold
1,041
– – 0.02% 399
2025
Q4 		$414K Buy
+1,041
New +$461K 0.02% 388

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prosperity Consulting Group's ALNY Position: Q1 2026 in Review

Prosperity Consulting Group held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 1,041 shares worth $344K. The position accounts for 0.02% of the portfolio, ranked #399.

Prosperity Consulting Group first reported a position in ALNY in Q4 2025 and has held it in 2 quarters since. The position peaked at $414K in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Prosperity Consulting Group held 1,041 shares of Alnylam Pharmaceuticals worth $344K as of Q1 2026.
  • Prosperity Consulting Group left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
  • Alnylam Pharmaceuticals made up 0.02% of Prosperity Consulting Group's portfolio in Q1 2026, its #399 holding.
  • Prosperity Consulting Group first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Prosperity Consulting Group's Alnylam Pharmaceuticals position peaked at $414K in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Prosperity Consulting Group's 13F filing for Q1 2026, filed 5 May 2026.